Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 20;123(8):303.
doi: 10.1007/s00436-024-08318-7.

Assessment of nebivolol efficacy in experimental models of toxoplasmosis: insights into parasite burden reduction and neuronal protection

Amanda Bruno da Silva Bellini Ramos  1 , Tayline Torres  2 , Luis Felipe Cunha Dos Reis  3 , Gabriel Carvalho Lambert  1 , Fábio Antônio Colombo  1 , Marcos José Marques  1 , Juliana Quero Reimão  4
Affiliations

Assessment of nebivolol efficacy in experimental models of toxoplasmosis: insights into parasite burden reduction and neuronal protection

Amanda Bruno da Silva Bellini Ramos et al. Parasitol Res. .

Abstract

This study investigates the efficacy of nebivolol (NBV) in experimental models of toxoplasmosis, focusing on parasite burden reduction and neuronal protection. In the acute model of experimental toxoplasmosis, Swiss mice infected with RH strain tachyzoites received oral NBV chlorhydrate doses of 2 mg/kg/day and 4 mg/kg/day for 8 days. Treatment with NBV significantly reduced parasite burden compared to vehicle and standard drug (PYR) groups. In the chronic model of experimental toxoplasmosis, C57/BL6 mice infected with the ME49 strain received NBV chlorhydrate 41 days post-infection and were evaluated after 10 days of treatment. NBV chlorhydrate effectively reduced cyst number and area, as well as bradyzoite burden compared to controls. Histological analysis demonstrated that NBV chlorhydrate preserved neuronal count, with the 4 mg/kg/day dose yielding counts similar to non-infected mice. Statistical analysis confirmed significant differences compared to control groups. Furthermore, immunohistochemical analysis revealed a significant reduction in iNOS labeling in the brains of mice treated with NBV chlorhydrate, indicating a decrease in nitric oxide production compared to control groups. These findings suggest NBV's potential as a promising candidate for toxoplasmosis treatment, highlighting its ability to reduce parasite burden and protect neuronal integrity. Further research is warranted to elucidate NBV's mechanisms of action and its clinical application in managing toxoplasmosis.

Keywords: Chronic Toxoplasmosis; Experimental models; In vivo; Nebivolol; Neuronal protection; Toxoplasmosis.

PubMed Disclaimer

References

    1. Abdulkareem NM, Bhat R, Powell RT, Chikermane S, Yande S, Trinh L, Abdelnasser HY, Tabassum M, Ruiz A, Sobieski M, Nguyen ND, Park JH, Johnson CA, Kaipparettu BA, Bond RA, Johnson M, Stephan C, Trivedi MV (2022) Screening of GPCR drugs for repurposing in breast cancer. Front Pharmacol 13:1049640. https://doi.org/10.3389/fphar.2022.1049640 - DOI - PubMed - PMC
    1. Alanazi AD, Alnomasy SF (2023) Immunomodulatory, antioxidant, and anti-inflammatory activities of green synthesized copper nanoparticles for treatment of chronic Toxoplasma gondii infection. Pharmaceuticals 7:1574. https://doi.org/10.3390/ph16111574 - DOI
    1. Ben-Harari RR, Goodwin E, Casoy J (2017) Adverse event profile of pyrimethamine-based therapy in toxoplasmosis: a systematic review. Drugs R D 17(4):523–544. https://doi.org/10.1007/s40268-017-0206-8 - DOI - PubMed - PMC
    1. Cockcroft J (2007) A review of the safety and efficacy of nebivolol in the mildly hypertensive patient. Vasc Health Risk Manag 3(6):909–917 - PubMed
    1. Daher D, Shaghlil A, Sobh E, Hamie M, Hassan ME, Moumneh MB, Itani S, El Hajj R, Tawk L, El Sabban M, El Hajj H (2021) Comprehensive overview of toxoplasma gondii-induced and associated diseases. Pathogens 10(11):1351

MeSH terms

LinkOut - more resources